Axial SpA Referral Strategies in Edinburgh and the Lothians

  • Research type

    Research Study

  • Full title

    Axial Spondyloarthritis Referral Strategies in Edinburgh and the Lothians (AxREAL)

  • IRAS ID

    350090

  • Contact name

    Jordan Hepburn

  • Contact email

    jordan.hepburn@nhslothian.scot.nhs.uk

  • Sponsor organisation

    Rachel Beaton

  • Duration of Study in the UK

    5 years, 1 months, 26 days

  • Research summary

    Axial Spondyloarthritis (AxSpA) is a progressive inflammatory disease which can have severe and complex impact on individuals. Individuals with AxSpA can experience chronic pain, health co-morbidities, poor quality of life and economic burden. There is a worldwide mean delay of 6.7 years from initial symptom presentation to healthcare and diagnosis by a Rheumatologist. Diagnostic delay is associated with more severe disease progression, structural spinal deformity, and potentially less efficacious medical treatment. AxSpA epidemiology, time to diagnosis and primary care referral strategy performance are empirically unknown in the Scottish GP population. This lack of insight extends to the impact of Advanced Practice Physiotherapists (APPs) on patient outcomes, who were introduced to General Practice as part of primary care redesign and integration. The AxREAL study aims to improve understanding of these phenomena within the Scottish Population. In so doing, the prior probability of AxSpA in General Practice will be determined, and optimal referral strategies will be identified based upon statistical modelling, health-economic analysis, and healthcare system feasibility. Thus findings are expected to have a tripartite of key outcomes: 1) support primary care clinicians’ in making decisions about referring patients for suspected AxSpA from GP, helping to reduce perceived uncertainty and the likelihood of patients experiencing diagnostic delay; 2) support design of effective primary care referral pathways to secondary care Rheumatology services, conducive to value based healthcare; 3) generate a quantifiable baseline in provision of care for people with symptoms associated with AxSpA in Scottish General Practice, providing a comparator for future healthcare service development and prospective research activity. These outcomes should ensure that the AxREAL study will positively impact patients, clinicians and healthcare services across NHS Scotland.

  • REC name

    North of Scotland Research Ethics Committee 2

  • REC reference

    25/NS/0062

  • Date of REC Opinion

    14 Jul 2025

  • REC opinion

    Further Information Favourable Opinion